V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Atea Pharmaceuticals Executive Compensation (FY25)

AVIR · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): June 22, 2026
276 figures on this page: 272 cited to the filing that reported them, 4 calculated from figures it prints. See the citations
Jean-Pierre Sommadossi, President, Chief Executive Officer and Chairman of the Board, received $3,403,752 in total compensation for fiscal 2025, and Sommadossi's total moved 19.0% lower from the $4,202,323 reported for fiscal 2024. Meanwhile, the say-on-pay proposal drew 94.1% of votes cast for or against in favor at the meeting held June 18, 2026 for fiscal 2025. Separately, companies named in the disclosed peer group include 89bio, Inc., Alector, Inc., Allakos Inc., AlloVir, Inc. and Anaptys Bio, Inc., among others. The fiscal 2025 disclosure covers 5 named executive officers.
Chief executive, fiscal 2025
◇
Jean-Pierre Sommadossi
Latest say-on-pay support
=
June 18, 2026
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Jean-Pierre Sommadossi: $4,202,323 → $3,403,752 (19.0% lower)
Say-on-pay support: 79.3% → 94.1% (14.8 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Atea Pharmaceuticals' chief executive and what were they paid?
Jean-Pierre Sommadossi, President, Chief Executive Officer and Chairman of the Board, received $3,403,752 in total compensation for fiscal 2025. Sommadossi's total moved 19.0% lower from the $4,202,323 reported for fiscal 2024.
What was Atea Pharmaceuticals' say-on-pay result?
The say-on-pay proposal drew 94.1% of votes cast for or against in favor at the meeting held June 18, 2026 for fiscal 2025.
Which companies are in Atea Pharmaceuticals' peer group?
Companies named in the disclosed peer group include 89bio, Inc., Alector, Inc., Allakos Inc., AlloVir, Inc. and Anaptys Bio, Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jean-Pierre Sommadossi
President, Chief Executive Officer and Chairman of the Board
◇—◇◇◇——◇
Janet Hammond
Chief Development Officer
◇—◇◇◇—◇◇
Andrea Corcoran
Chief Financial Officer, Executive Vice President, Legal
◇—◇◇◇—◇◇
Maria Arantxa Horga
Chief Medical Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jean-Pierre Sommadossi
President, Chief Executive Officer and Chairman of the Board
◇—◇◇◇——◇
Janet Hammond
Chief Development Officer
◇—◇◇◇—◇◇
Andrea Corcoran
Chief Financial Officer, Executive Vice President, Legal
◇—◇◇◇—◇◇
Maria Arantxa Horga
Chief Medical Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jean-Pierre Sommadossi
President, Chief Executive Officer and Chairman of the Board
◇—◇◇◇——◇
Janet Hammond
Chief Development Officer
◇—◇◇◇—◇◇
Andrea Corcoran
Chief Financial Officer, Executive Vice President, Legal, and Secretary
◇—◇◇◇—◇◇
Maria Arantxa Horga
Chief Medical Officer
◇—◇◇◇—◇◇
John Vavricka
Chief Commercial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Andrea CorcoranOPTION◇——◇—◇◇
Andrea CorcoranPSU◇◇◇—◇—◇
Janet HammondOPTION◇——◇—◇◇
Janet HammondPSU◇◇◇—◇—◇
Jean-Pierre SommadossiPSU◇◇◇—◇—◇
Jean-Pierre SommadossiOPTION◇——◇—◇◇
John VavrickaPSU◇◇◇—◇—◇
John VavrickaOPTION◇——◇—◇◇
Maria ArantxaPSU◇◇◇—◇—◇
Maria ArantxaOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Maria HorgaPSU◇◇——
Option◇—◇1/30/2035
Option◇—◇1/30/2032
RSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇1/30/2034
PSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇1/30/2033
Janet HammondRSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇1/30/2034
Option◇—◇1/30/2035
RSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇1/30/2032
Option◇—◇1/30/2033
RSU◇◇——
PSU◇◇——
Andrea CorcoranPSU◇◇——
Option◇—◇1/30/2033
Option◇—◇1/30/2034
Option◇—◇1/30/2035
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇1/30/2032
Jean-Pierre SommadossiOption◇—◇1/30/2032
Option◇—◇1/30/2034
Option◇—◇1/30/2035
RSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇1/30/2033
RSU◇◇——
Option◇—◇1/30/2034
John VavrickaOption◇—◇1/30/2023
RSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇1/30/2024
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇1/30/2035
PSU◇◇——
RSU◇◇——
Option◇—◇1/30/2032
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Arthur Kirsch
◇—◇———◇
Howard Berman
◇—◇———◇
Franklin Berger
◇◇◇———◇
Barbara Duncan
◇◇◇———◇
Bruno Lucidi
◇◇◇———◇
Jerome Adams, Polly Murphy, Bruce Polsky and Jean-Pierre Sommadossi served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance member◇
Equity is delivered as Options and RSUs.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • 89bio, Inc. ETNB
  • Alector, Inc. ALEC
  • Allakos Inc. ALLK
  • AlloVir, Inc. symbol not shown
  • Anaptys Bio, Inc. ANAB
  • Arbutus Biopharma Corporation ABUS
  • Arcturus Therapeutics Holdings, Inc. ARCT
  • Assembly Biosciences, Inc. ASMB
  • Chimerix, Inc. CMRX
  • Enanta Pharmaceuticals, Inc. ENTA
  • Gossamer Bio, Inc. GOSS
  • Inozyme Pharma, Inc. INZY
  • Invivyd, Inc. IVVD
  • Kodiak Sciences Inc. KOD
  • Replimune Group, Inc. REPL
  • Scholar Rock Holding Corporation SRRK
  • Vir Biotechnology, Inc. VIR
  • Y-mABs Therapeutics, Inc. YMAB

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 18, 2026=◇◇◇
2024June 20, 2025=◇◇◇
2023June 21, 2024=◇◇◇
2021June 16, 2022=◇◇◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Atea Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Atea Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Atea Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Atea Pharmaceuticals' disclosed peer group is defensible, who names Atea Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
276 figures on this page: 272 cited to the filing that reported them, 4 calculated from figures it prints.
272 cited to the filing
4 calculated from the filing

Documents cited

  1. 0001193125-26-277639
  2. 0001193125-26-182293
    2025 Director Compensation Table · 2025 Summary Compensation Table · Director Compensation · Grants of Plan-Based Awards · and 2 more sections
  3. 0001193125-25-143750
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001193125-25-104019
    Summary Compensation Table
  5. 0001193125-24-165886
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0000950170-24-049178
    NAMED EXECUTIVE OFFICER COMPENSATION · Summary Compensation Table
  7. 0001193125-23-171257
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Atea Pharmaceuticals executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/AVIR (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Atea Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Atea Pharmaceuticals discloses

The companies named in AVIR's own disclosed peer group.

Replimune Group, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy